1Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral ther apy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5: 890-897.
2Lai CL, Gane E, Liaw YF, el al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007, 357:2576- 2588.
3Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nueleoside-treated hepatitis B patients. Hepatology, 2006,44 (4 Suppl. 1):230A (abstract 112).
5Hou J, Yin YK, Xu D,et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-bllnd trial. Hepatology, 2008, 47:447-454.
6Zeuzem S, Buti M, Gane EJ, el al. Baseline parameters predict both early virologic response and longer term outcomes for telbivu dine-treated patients with chronic hepatitis B (The GLOBE Study). Hepatology, 2007, 46(Suppl 1) :681A.
7Reddy KR, Rustgi V, Zeuzem S, et al. Week 24 is the optimal time point for predicting outcomes at 2 years with telbivudine. Global Antiviral J, 2007, 121(Suppl. 2):13 (Abstract 12).
8Standring DN, Patty A, Chapron C, et al. Resistance determina tion in patients experiencing virologic breakthrough following telbi vudine or lamivudine therapy in the international GLOBE trial DDW, 2007, Poster Abstract S1781.
9Gane E, Lai CL, Min A, et al. Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the GLOBE study. J Hepatology, 2007, 46 (Suppl 1): S187.
二级参考文献9
1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
2Lok AS, McMahon B J; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology, 2004, 39: 857-861.
3Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
4Mangi A, Villani MR, Minerva N, et al. Efficacy of 5MU of interferon in combination with ribavirin for naive patients with chronic hepatitis C virus: a randomized controlled trial. J Hepatol, 2001,34: 441-446.
5Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology, 2003,37: 600-609.
6Strader DB, Waright T, Thomas DL, et al. Diagnosis, management,and treatment of hepatitis C. Hepatology, 2004, 39: 1147-1171.
7Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis Bviremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis, 1999, 180: 1757-1762.
8Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 2001, 34: 785-791.
9Jang JW, Bae SH, Chio JY, et al. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg response. J Gastroenterol Hepatol, 2006, 21: 384-391.
8Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
